Hyperuricemia News Archive
Data show that gout is associated with an increased risk of developing erectile dysfunction.
A study of Medicare patients found that atrial fibrillation was nearly twice as likely to develop in those with vs without gout.
Serum uric acid levels above the median prior to cardiac surgery is independently associated with 5.5-fold increased odds of postoperative acute kidney injury.
Association showed increased risk of all-cause, cardiovascular, and cancer death.
Medication adherence also remained low in patients who reinitiate treatment after a gap in therapy.
Serum urate level is a strong predictor of incident gout, but only about half of patients with hyperuricemia develop clinically evident gout.
US study documents a 27% increase in visits to emergency departments for a primary diagnosis of acute gout from 2006 to 2014.
From 2006 to 2014 in Ireland, the prevalence of hyperuricemia increased from 19.7% to 25.0% among men and from 20.5% to 24.1% among women.
All-cause and cardiovascular mortality risks were 22% and 34% higher among febuxostat-treated patients vs allopurinol recipients.
In a study, CKD patients with high trajectories of serum uric acid had nearly triple the risk for ESRD and 4.5 times the risk for death.
Among CKD patients with an eGFR of 45 mL/min/1.73 m2 or above, each 1 SD increase in baseline uric acid levels is independently associated with a 40% increased risk of kidney failure.
Febuxostat may increase the risk for heart-related death.
Uric acid-lowering therapy might improve kidney outcomes, including kidney failure events, proteinuria, and the rate of change in eGFR, and seem to reduce the risk of cardiovascular events in adults with CKD.
Each 1 standard deviation in baseline uric acid levels was associated with a significant 80% increased odds of rapid kidney function decline.
In a study of African Americans with hypertension-related CKD, metoprolol, but neither ramipril nor amlodipine, increased serum uric acid levels.
The risk for developing erectile dysfunction is 15% higher among men with than without gout.
All-cause hospitalizations in the US increased 410% from 1993 to 2014 among gout sufferers compared with 4.8% in the general population.
A DASH-style diet is associated with a reduced risk of gout, whereas a Western diet is associated with a higher risk.
Gout is uncontrolled in the majority of individuals with the condition, data show.
The multivariable-adjusted relative risk of hip fracture was 1.38 in women with history of gout.
Blacks had significantly higher median baseline serum urate levels compared to whites.
The allopurinol group had a significant 0.10 mg/dL lower final creatinine level than controls.
The DASH diet lowered serum uric acid, and this effect was greater among participants with hyperuricemia.
Odds of acute kidney injury increases by 29% with each 1 mg/dL increment in uric acid level at ICU admission.
Benefit of adding the uricosuric drug to a xanthine oxidase inhibitor persists for up to 2 years, extension study shows.
The guidelines recommend treatment strategies and state that evidence is insufficient to support therapy to lower uric acid to target levels.
Zurampic, a URAT1 inhibitor, can be combinated with a xanthine oxidase inhibitor to treat hyperuricemia tied to gout.
Serum uric acid levels of 10 mg/dL or higher are associated with an increased risk for nephrolithiasis.
Using the drug together with allopurinol helps more patients achieve target uric acid levels of less than 6 mg/dL.
In a study, CKD was 16% less likely to develop in low adherers to a DASH dietary pattern.
The effect of gout on type 2 diabetes risk was more profound in women than men.
Highest vs lowest uric acid levels associated with a 2-fold increased risk of VTE.
A higher allopurinol dose was protective against renal failure in elderly allopurinol recipients.
Odds of non-fatal stroke are 49% higher in patients in the fourth quartile of uric acid level versus those in the second quartile.
Patients with inadequately controlled gout experience lower quality of life and report worse functioning.
Unlike in adults, there is no association between uric acid, cardiorenal parameters.
Patients treated with the uric acid-lowering drug were less likely to experience a greater than 10% decline in eGFR than placebo recipients.
The highest vs. lowest quartile of serum uric acid is associated with a 3.4-fold increased risk of end-stage renal disease.
Gout is associated with an elevated risk of comorbid conditions, especially hypertension and alcohol abuse.
Highest vs. lowest quartile associated with a 17% increased risk.
Association strongest with cardiovascular mortality in the elderly.
Gout is associated with an elevated likelihood of both organic and psychogenic ED.
Proteinuria, hyperphosphatemia, anemia linked more rapid annual decline in eGFR.
Gout increased the risk of erectile dysfunction in men by 21%.
Increased uric acid levels were correlated with decreased HbA1c and increased prevalence of diabetic kidney disease, study finds.
Guidelines currently don't recognize gout as a risk factor for CKD and nephrolithiasis.
The incidence of gout among CKD patients was 6.82 per 1,000 persons per year compared to 2.43 for those without the disease.
The risk for gout flares was 236% higher overnight than in the day.
Although 87% of patients met the criteria for urate-lowering treatment within 5 years, only 30% were prescribed the recommended treatment.
Even levels in the normal range can be associated with an increased risk of renal insufficiency.
Researchers concluded that hyperuricemia is a probable cause of hemospermia.
Analysis found that cigarette smoking was associated with a 24% overall reduction in gout risk.
Women with this form of arthritis are more susceptible to diabetes, researchers say.
Each 5-unit increment in BMI is associated with a 55% increased relative risk of gout.
Allopurinol therapy is not associated with beneficial cardiovascular outcomes in gout patients.
In a study, donors were 60% more likely to be diagnosed with gout than matched healthy controls.
Likelihood of a recurrent gout attack is greater under conditions of high temperature and/or low relative humidity.
Renal function decline is not accelerated, however.
Korean study also revealed an inverse association between serum homocysteine levels and renal function.
An Israeli study shows that serum uric acid levels can be a clinically useful nutritional marker.
Patients with hyperuricemia who use urate-lowering therapies are less likely to experience renal function decline.
A level of 7 mg/dL or higher is associated with a 62% increased risk compared with lower levels.
Elevated levels of uric acid are associated with an increased likelihood of diabetes.
Patients with coronary artery disease are more likely to have ED if they have elevated uric acid levels.
After diabetes is diagnosed, however, uric acid levels fall, study finds.
Serum level before procedure is an independent predictor of stent restenosis.
Individuals with first-degree relatives affected by the condition are twice as likely as those in the general population to experienced gout.
Patients with hyperuricemia also had a high prevalence of lower urinary tract symptoms.
Elevated uric acid levels are associated with increased risk of ischemic heart disease and blood pressure, but appear unlikely to cause these problems, a study found.
Patients with gout experienced no clinically significant urate-lowering effects from an 8-week course of a modest dosage of vitamin C.
Systemic review suggests allopurinol can significantly improve estimated glomerular filtration rates.
Adverse events included skin rash, gastrointestinal problems, and allopurinol hypersensitivity syndrome.
Gout prevalence is higher among patients with lower average estimated glomerular filtration rates or higher levels of albuminuria
The two are linked regardless of gender, race, and obesity.
An consumption over a two-year period found to decrease likelihood of a gout attack by 35%.
Data from 5,707 participants of the National Health and Nutrition Examination Survey (NHANES) 2007-2008 show that gout now affects 4% of Americans (8.3 million individuals), and hyperuricemia, 21% (43.3 million).
PARIS—High levels of uric acid are associated with an increased risk of chronic kidney disease (CKD), especially among hypertensive individuals.
Elevated blood pressure is twice as likely in those with a serum uric acid level of 5 mg/dL or higher
Gout patients have an increased prevalence of simple renal cysts, and these cysts are associated with a decreased likelihood of kidney stone disease, according to Brazilian investigators.
PHILADELPHIA—Patients with chronic kidney disease (CKD) have a relatively high prevalence of gout compared with the general population, according to data presented at Kidney Week 2011.
CHICAGO—Uncontrolled serum uric acid in patients with gout is associated with an increased risk of developing kidney disease and diabetes, according to the findings of two studies presented at the American College of Rheumatology annual meeting.
High uric acid concentrations are associated with lower all-cause and cardiovascular mortality among hemodialysis (HD) patients, according to an international study.
VANCOUVER, B.C.—Elevated serum uric acid levels strongly predict development of albuminuria in patients with chronic kidney disease (CKD), according to researchers in Romania.
WASHINGTON, D.C.—Elevated serum uric acid levels may be a marker for an increased risk of erectile dysfunction (ED), Iranian researchers reported at the American Urological Association 2011 annual meeting.
VANCOUVER, B.C.—Allopurinol can be prescribed safely to treat recurrent gout in renal transplant recipients who are receiving azathioprine, British researchers reported.
The FDA has ordered a halt to the marketing of unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of familial Mediterranean fever.
Savient Pharmaceuticals, Inc., of East Brunswick, N.J., has received FDA clearance to market Krystexxa (pegloticase) as a treatment for chronic gout in adult patients refractory to conventional treatment.
Higher serum uric acid (SUA) levels may independently contribute to the development of CKD, data suggest.
MUNICH, GERMANY—Allopurinol, a drug long used to treat gout, can cause regression of left ventricular hypertrophy (LVH) and improvement of endothelial dysfunction in CKD patients, a study found.
Allopurinol, a drug used to treat gout, may slow progression of kidney disease in CKD patients, according to new findings scheduled to be published in an upcoming issue of the Clinical Journal of the American Society of Nephrology.
Colcrys, a new colchicine formulation, has received marketing clearance for the prevention of gout flares.
The FDA's Arthritis Drugs Advisory Committee has recommended that Krystexxa (pegloticase) be approved for treating refractory chronic gout.
Hyperuricemia increases the risk of death from any cause and from cardiovascular disease (CVD) in patients with CKD stages 3 to 4, according to a report in the American Journal of Kidney Diseases (2009; published online ahead of print).
A new oral medication that reduces serum uric acid levels has received FDA approval for treating hyperuricemia in patients with gout.
A short course of a corticosteroid could supplant nonsteroidal anti-inflammatory drugs (NSAIDs) as the medication of choice to treat gout, Dutch researchers suggest.
ORLANDO, Fla.—Patients with metabolic disorders are more likely to develop uric acid stones than other types, and arteriosclerotic diseases and hyperuricemia strongly predict the presence of these stones, researchers reported here at the American Urological Association annual meeting.
Hyperuricemia may be strongly associated with CKD in African Americans.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)